People with wet age-related macular degeneration (AMD) often need eye injections every one to two months to keep fluid from damaging the retina. A treatment that lasts six months would be a big relief. In October 2026, one such candidate, the vorolanib intravitreal insert (Duravyu; EyePoint), fell short in its second large trial. Here is what happened, in plain terms.
The LUCIA trial
LUCIA enrolled 475 people aged 50 or older with active wet AMD; their average age was about 77. After three monthly aflibercept injections, patients got either the insert every 24 weeks or aflibercept 2 mg every 8 weeks. Both groups could get extra aflibercept if vision dropped and new fluid appeared.
What the results showed
- Vision: insert-treated eyes gained an average of 2.5 letters at weeks 52 to 56, compared with 6.1 letters with aflibercept. That difference was outside the pre-set margin, so the insert was not shown to be “noninferior.”
- Treatment burden: insert patients needed an average of 3.3 injections after the loading phase versus 5.3 with aflibercept, a 38% reduction. About half (52%) needed no extra injection through week 56.
- Retina swelling: thickness fell by 66 microns with the insert and 82 with aflibercept.
- Side effects: severe inflammation and infection were under 1% in both groups, but bleeding on the eye surface, floaters, retinal and vitreous hemorrhage, and pressure rises were more common with the insert. Data are preliminary.
An earlier identical trial, LUGANO (432 patients), also missed its main goal in the full dataset. The company announced it would end both wet AMD trials early, cut its workforce by about 53%, and focus on diabetic macular edema.
What this means for you
- Current approved injections remain the standard. Do not stretch your schedule on your own.
- Longer-lasting options are still being studied; fewer visits only help if vision is protected too.
- Check each eye separately at home with an Amsler grid or a door frame, and call your retina specialist promptly for new distortion.
Readers in the Conejo Valley can find local eye health news at a Westlake Village eye care blog.
Our office does not treat macular degeneration; we refer to retina specialists. I share results like these so patients understand why “less often” is only good news when the vision results hold up.
Source: Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial (Ophthalmology Times / Modern Retina, 10/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.